Taiho, Memorial Sloan Kettering Cancer Center and Hartford HealthCare contributed to a round that boosted the cancer drug developer's total funding to more than $175m.
US-based oncology drug developer Oric Pharmaceuticals has closed a $55m series D round that included pharmaceutical company Taiho, cancer researcher Memorial Sloan Kettering Cancer Center and healthcare provider Hartford HealthCare.
Investment firms Arrowmark Partners and Invus Opportunities co-led the round, which included financial services and investment group Fidelity Management & Research (FMR), Casdin Capital, The Column Group (TCG), TopSpin Partners, OrbiMed, EcoR1 Capital, City Hill Ventures, Kravis Investment Partners and Foresite Capital.
Taiho participated in the round through its corporate…
